International Journal of Hematology

, Volume 96, Issue 3, pp 308–319 | Cite as

Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients

Original Article

Abstract

We retrospectively investigated increases in large granular lymphocytes (LGL) in peripheral blood during dasatinib treatment in 25 chronic myelogenous leukemia patients. Fifteen of 25 patients (60 %) showed an increase in LGL. All 15 of these patients also showed an increase in NK cells, and 11 showed an increase in CD8+ T cells. High frequencies of clonal rearrangements of TCR-β, -γ, and -δ genes were observed in LGL (+) patients, and at lower frequencies in LGL (−) patients as well. Clinical responses were favorable for all. With respect to their newly obtained complete molecular response after dasatinib treatment, LGL (+) patients showed higher response rates than did LGL (−) patients. In contrast, pleural effusions were more commonly observed in LGL (+) patients (60 %) than in LGL (−) patients (20 %). LGL counts significantly increased at 2 h after oral intake of dasatinib in all 25 patients. This was not observed in treatment with imatinib or nilotinib. Cytomegalovirus (CMV) C7-HRP tests were negative in all patients. Serum CMV-IgM antibodies were positive in only 2 of 25 patients without symptom of infection. Thus, LGL lymphocytosis during dasatinib treatment may be correlated with favorable molecular response, and with increased incidence of pleural effusions. In the clinical setting, CMV reactivation appears uncommon.

Keywords

CML LGL Dasatinib TCR CMV 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366–77.PubMedCrossRefGoogle Scholar
  3. 3.
    Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol. 2009;37:256–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Chen J, Schmitt A, Chen B, Rojewski M, Rubeler V, Fei F, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest. 2009;39:1098–109.PubMedCrossRefGoogle Scholar
  8. 8.
    Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398–405.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799–807.PubMedCrossRefGoogle Scholar
  11. 11.
    Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res. 2011;35:e1–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587–97.PubMedCrossRefGoogle Scholar
  13. 13.
    Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:668–79.PubMedCrossRefGoogle Scholar
  14. 14.
    Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Ravandi F. Dasatinib, an immunomodulator? Blood. 2010;116:673–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011;25:201–10.PubMedCrossRefGoogle Scholar
  19. 19.
    van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.PubMedCrossRefGoogle Scholar
  20. 20.
    Eizuru Y, Minematsu T, Minamishima Y, Ebihara K, Takahashi K, Tamura K, et al. Rapid diagnosis of cytomegalovirus infections by direct immunoperoxidase staining with human monoclonal antibody against an immediate-early antigen. Microbiol Immunol. 1991;35:1015–22.PubMedGoogle Scholar
  21. 21.
    Gondo H, Minematsu T, Harada M, Akashi K, Hayashi S, Taniguchi S, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol. 1994;86:130–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 1996;87:2476–85.PubMedGoogle Scholar
  23. 23.
    Silla LM, Pincus SM, Locker JD, Glover J, Elder EM, Donnenberg AD, et al. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/ABL-positive targets. Br J Haematol. 1996;93:375–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:387–98.PubMedCrossRefGoogle Scholar
  25. 25.
    Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529–34.PubMedGoogle Scholar
  26. 26.
    Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Lowin-Kropf B, Kunz B, Schneider P, Held W. A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors. Eur J Immunol. 2002;32:773–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med. 1999;190:1189–96.PubMedCrossRefGoogle Scholar
  29. 29.
    Pignata C, Prasad KV, Hallek M, Druker B, Rudd CE, Robertson MJ, et al. Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol. 1995;165:211–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–14.PubMedCrossRefGoogle Scholar
  31. 31.
    de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol. 2005;23:973–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Imagawa J, Tanaka H, Matsumoto K, Morita K, Harada Y, Harada H (2012) A sharp fluctuation in peripheral blood cells shortly after dasatinib administration. Int J Hematol (in press)Google Scholar
  34. 34.
    Mustjoki S, Rousselot P, Jalkanen S, Kreutzman A, Melo T, Lahesmaa A-M, et al. Dasatinib induce a rapid, dose-controllable mobilization of cytotoxic lymphocytosis: A novel immunomodulatory effect associated with prolonged therapy responses in advanced leukemia. #1204, The 52th ASH Annual Meeting and Exposition. 2010.Google Scholar
  35. 35.
    Al-Ameri A, Kantarjian H, Borthakur G, Bahceci E, Szatrowski T, Damokosh A, et al. Opportunistic infection are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CP-CML). #1120, The 51th ASH Annual Meeting and Exposition. 2009.Google Scholar

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  1. 1.Department of HematologyHiroshima City Asa HospitalHiroshimaJapan
  2. 2.Department of Clinical LaboratoryHiroshima City Asa HospitalHiroshimaJapan

Personalised recommendations